Drug results: 2

tegomil fumarate Riulvy, active substance tegomil fumarate, is a medicine used to treat multiple sclerosis, a disease in which the immune system (the body’s natural defences) attacks the protective insulation around nerves (myelin) in the brain and spinal cord, causing inflammation and damage to the nerves themselves. The mechanism by which tegomil fumarate exerts therapeutic effects in multiple sclerosis is not fully understood. Tegomil fumarate acts via the major active metabolite, monomethyl fumarate. Preclinical studies indicate that monomethyl fumarate pharmacodynamic responses appear to be primarily mediated through activation of the Nuclear factor (erythroid derived 2)-like 2 (Nrf2) transcriptional pathway. Dimethyl fumarate has been shown to up regulate Nrf2-dependent antioxidant genes in patients (e.g. NAD(P)H dehydrogenase, quinone 1; [NQO1]).
diroximel fumarate The mechanism by which diroximel fumarate exerts therapeutic effects in MS is not fully understood. Diroximel fumarate acts via the major active metabolite, monomethyl fumarate. Preclinical studies indicate that the pharmacodynamic responses of monomethyl fumarate appears to be mediated, at least in part, through activation of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway. Dimethyl fumarate has been shown to up regulate Nrf2-dependent antioxidant genes in patients.

DrugCentral Search Overview